Department of Nephrology, Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Department of Nephrology, Guangdong General Hospital, Guangzhou, 510030, China.
Sci Rep. 2016 Dec 20;6:38768. doi: 10.1038/srep38768.
Limited data are available on epidemiology and drug use in Chinese hypertensive patients with chronic kidney disease (CKD). We determined the prevalence; awareness, treatment, and control rates of hypertension; anti-hypertensive use, expenditure pattern; and factors associated with hypertension prevalence and control in Chinese patients with CKD. This was one of the largest cross-sectional surveys that enrolled 6079 CKD participants (mean age, 51.0 ± 16.37 years) with or without hypertension from 22 centres across China. The prevalence, awareness, and treatment rates were 71.2%, 95.4%, and 93.7%, respectively. Control rates 1 and 2 (Blood pressure, BP <140/90 and <130/80 mmHg) were 41.1% and 15.0%, respectively. Patients were treated mostly with monotherapy (37.7%) or 2-drug anti-hypertensive combination (38.7%). Factors associated with prevalence of hypertension included age; smoking; body mass index; physical exercise; family history of hypertension; hyperuricaemia; and CKD. Control rate was associated with CKD stage, BP monitoring at home, and use of drug combinations. Despite high rates of awareness and treatment, the control rates are low. CKD stages 4 and 5 adversely affect the control rate. The results suggest the immediate need of comprehensive controlling measures to improve the control of hypertension in Chinese patients with CKD.
中国慢性肾脏病(CKD)高血压患者的流行病学和药物使用数据有限。我们确定了中国 CKD 高血压患者的患病率;高血压知晓率、治疗率和控制率;抗高血压药物使用、支出模式;以及与高血压患病率和控制率相关的因素。这是中国 22 个中心进行的最大的横断面调查之一,共纳入了 6079 名 CKD 患者(平均年龄 51.0±16.37 岁),包括有或无高血压患者。患病率、知晓率和治疗率分别为 71.2%、95.4%和 93.7%。控制率 1 和 2(血压 <140/90 和 <130/80mmHg)分别为 41.1%和 15.0%。患者主要接受单药治疗(37.7%)或 2 种降压药物联合治疗(38.7%)。与高血压患病率相关的因素包括年龄;吸烟;体重指数;体育锻炼;高血压家族史;高尿酸血症;以及 CKD。控制率与 CKD 分期、家庭血压监测和药物联合使用有关。尽管知晓率和治疗率较高,但控制率较低。CKD 4 期和 5 期会降低控制率。结果表明,需要立即采取综合控制措施,以提高中国 CKD 患者的高血压控制率。